Australian biotech company
Dec 18, 2018
HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer’s; Bristol-Myers, H3 Biomedicine discover RNA splicing
HER2 Vaccine Candidate Meet Phase 1b Study An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, successfully finished its phase 1b clinical trial and head to a phase 2 study. The first tranche of data from the 14-patient trial comes...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
